Details

Autor(en) / Beteiligte

• Garnica-Cuéllar, Juan C
• Lavalle-González, Fernando J
• Magaña-Serrano, José A
• Almeda-Valdés, Paloma
• Cetina-Canto, José A
• Chávez-Iñíguez, Jonathan S
• Garza-García, Carlos A
• González-Chávez, Antonio
• González-Gálvez G, Guillermo
• Medina-Chávez, Juan H
• Pimentel-Morales, Gela
• Sánchez-Pedraza, Valentín

Titel

Consensus on the use of iSGLT2 in the treatment of patients with type 2 diabetes mellitus

Ist Teil von

• Gaceta médica de México, 2022-01, Vol.158 (Monografic 1), p.1

Ort / Verlag

Mexico

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Although in recent years in Mexico the quality of diabetes mellitus (DM) care has improved and access to health services and medications has increased, there is a lack of adherence to the recommendations of the clinical guidelines, which could explain the poor glycemic control in many of the patients with DM. Sodium-glucose cotransporter type 2 (iSGLT2) inhibitors have been the last class of antidiabetic agents to receive approval from the Food and Drug Administration (FDA) and COFEPRIS (Mexico). In order to improve the use of SGLT2i in clinical practice in Mexico, this paper presents the recommendations issued by a panel of eleven Mexican experts based on the new published evidence for the treatment of patients with DM2.